BetriXa™

Betrixaban
Anticoagulant (Cardiovascular Preparations)

Indication:

Betrixaban is indicated for the prophylaxis of Venous Thromboembolism (VTE) in adult patients hospitalized for an acute medical illness and at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.

Dosage & Administration:

Recommended Dose: The recommended dose is an initial single dose of 160 mg, followed by 80 mg once daily. Daily oral doses should be given at the same time of day with food. The recommended duration of treatment is 35 to 42 days.

For Severe Renal Impairment: No dose adjustment is needed for mild or moderate renal impairment (CrCl> 30 mL/min). For patients with severe renal impairment (CrCl ≥ 15 to < 30 mL/min) the recommended dose of Betrixaban is an initial single dose of 80 mg followed by 40 mg once daily.

For Hepatic Impairment: No dose adjustment is required in patients with mild hepatic impairment. Avoid use in patients with moderate to severe hepatic impairment.

Preparation:

BetriXa^™ 40 Capsule: Each box contains 10 capsules in blister pack.
BetriXa^™ 80 Capsule: Each box contains 10 capsules in blister pack.